2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06B.15 Targetable Genetic Alterations Associated with Non-Small Cell Lung Cancer Mortality

Pdf Summary

This study examines the association between targetable genetic alterations and mortality in patients with Non-Small Cell Lung Cancer (NSCLC), highlighting the evolving role of biomarker testing and targeted therapy in this context. Using a retrospective multi-center approach, the study analyzes data from 9,834 NSCLC patients, with 38.8% undergoing biomarker testing between 2013 and 2020.<br /><br />The research focuses on several genetic alterations, including mutations or amplifications in KRAS, EGFR, MET, BRAF, ERBB2, and rearrangements in ALK, ROS1, and RET. It uses Cox regression analysis to evaluate overall mortality at 1- and 3-year intervals, adjusting for factors like age, sex, race, smoking status, cancer stage, and histologic subtype.<br /><br />Key findings indicate that EGFR and ALK alterations significantly associate with lower mortality rates, suggesting a positive prognostic value and improved survival outcomes when targeted therapies are applied. Conversely, MET and ROS1 alterations show higher mortality rates. The data suggest that the presence of EGFR mutations is most prevalent in the tested population and is linked to better survival outcomes, highlighting the importance of integrating biomarker testing in the comprehensive management plan for advanced NSCLC.<br /><br />The study underscores the transformative impact of targeted therapy on NSCLC management, documenting advancements from 2011 onwards in recommending biomarker testing for improved prognostic insights and treatment outcomes. However, while certain genetic markers such as EGFR and ALK demonstrate clear benefits, the prognostic implications for other targets remain less definitive and warrant further investigation.<br /><br />Ultimately, the study affirms the critical role of personalized medicine and targeted treatments in enhancing survival rates for NSCLC patients, emphasizing the need for continued evolution of testing guidelines and therapeutic strategies.

Asset Subtitle

Haley Tupper

Meta Tag

Speaker Haley Tupper

Topic Pathology and Biomarkers

Keywords

NSCLC

genetic alterations

biomarker testing

targeted therapy

mortality

EGFR

ALK

personalized medicine

survival outcomes

Cox regression analysis